The UK inhalable drug market is anticipated to grow at a CAGR of 2.0% during the forecast period (2020-2026). The key factor that drives the growth of the market includes the increased prevalence of respiratory and non-respiratory diseases across the country. As per the Health and Safety Executive 2019, COPD is among one of the serious causes of death in the country. As per the Institute for Health Metrics and Evaluation (IHME), in 2017, the prevalence of tracheal, bronchus, and lung cancer in the country is more than 95,000 in the country, whereas, the prevalence of lung cancer in the country was nearly 5.4 million. Thus, such a high prevalence of respiratory disease is likely to create a wide scope for the market. Further, government support along with the key player’s contributions is likely to enhance the market growth over the forecast period.
Get Free Sample link @ https://www.omrglobal.com/request-sample/uk-inhalable-drugs-market
The UK inhalable drug market has been segmented on the basis of the application and route of administration. Based on the application, the market is bifurcated into respiratory disease and non-respiratory diseases. The respiratory disease segment is likely to hold a significant share over the forecast period. Based on the route of administration, the market is segmented into the nasal inhalable drug and mouth inhalable drugs. The mouth segment is likely to contribute a significant share over the forecast period.
A full report of UK Inhalable Drugs Market available @ https://www.omrglobal.com/industry-reports/uk-inhalable-drugs-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
UK Inhalable Drugs Market by Type
- Hydrofluoroalkane inhalers (HFA)
- Dry powder inhalers (DPI)
- Soft mist inhalers (SMI)
- Others
UK Inhalable Drugs Market by Applications
- Respiratory Diseases
- Non- Respiratory Diseases
UK Inhalable Drugs Market by Route of Administration
- Nasal
- Mouth
Company Profiles
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Sanofi SA
- Synairgen Plc
- Vectura Group Plc
- Verona Pharma plc
- Zambon S.p.A.
The Report covers:
- Comprehensive research methodology of the UK Inhalable Drugs market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the UK Inhalable Drugs market.
- Insights about market determinants which are stimulating the UK Inhalable Drugs market.
- Detailed and extensive market segments with regional distribution of forecast revenues.
- Extensive profiles and recent developments of the market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-inhalable-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
